IL22 and breast cancer: Additionally, a study has shown that IL-22 released by Th17 cells can activate the MAP3K8 signaling pathway in BC cells, which in turn activates the STAT3 and AP-1 pathways, thereby increasing breast cancer aggressiveness [98].